Patent Protection Policy in the Therapeutic Group of Statins

Enantiomers Novelty Protection and its Influence on Generic Market: An Example with Escitalopram Patent Protection

“…the introduction of new product formulations appears to be a common strategy for attempting to extend the market exclusivity for medications facing impending generic entry (17). the patent policy of the manufacturer of the original product follows a similar pattern for enantiomers, as other researches have shown (20,27), e.g. more patents around the date of expiration of the main patent, more patents for use or new therapeutic effect.…”

“…comments and published cases were reviewed for consistency in the claim data and court decisions, to explore the length of the time period for protection of racemic and enantiomer molecules. then, a three-step patent search methodology, which was previously described, was applied to explore the differences in the patent protection policy (20). First, the patent expiration date was clarified, then the EPO database was searched with the keyword "escitalopram", and an expanded search was performed via the inPADoc patent family system to clarify the geographic protection.…”

Chirality as a Patent Protection Policy—An Example with Citalopram

“…A three-step search methodology was applied that was previously described (23). First the patent expiration date was clarified, then the EPO database was searched with the key word 'citalopram', and an expanded search was performed via the INPADOC patent family system to clarify the geographic protection.…”